Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

109.45USD
4:00pm EDT
Price Change (% chg)

$1.16 (+1.07%)
Prev Close
$108.29
Open
$109.60
Day's High
$109.88
Day's Low
$108.47
Volume
887,621
Avg. Vol
1,155,601
52-wk High
$114.95
52-wk Low
$80.34

AMGN.OQ

Chart for AMGN.OQ

About

Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the... (more)

Overall

Beta: 0.51
Market Cap (Mil.): $81,214.96
Shares Outstanding (Mil.): 749.98
Dividend: 0.47
Yield (%): 1.74

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 18.21 47.13 37.76
EPS (TTM): 5.95 -- --
ROI: 9.97 -2.58 18.76
ROE: 23.03 -2.66 19.59
Search Stocks

Amgen profit tops Wall Street view; rebounds from first quarter

- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.

30 Jul 2013

UPDATE 2-Amgen profit tops Wall Street view; rebounds from 1st qtr

July 30 - Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its medicines rebounded from a disappointing first quarter.

30 Jul 2013

Amgen profit tops Wall Street view; rebounds from first quarter

- Amgen Inc , which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.

30 Jul 2013

Amgen profit ex-items tops Wall Street view; rebounds after 1st qtr

July 30 - Amgen Inc, which is attempting to buy Onyx Pharmaceuticals Inc to add to its cancer drug offerings, on Tuesday reported higher-than-expected second- quarter profit as sales of many of its drugs rebounded from a disappointing first quarter.

30 Jul 2013

Exclusive: Amgen lines up BofA, JPM, Barclays to finance Onyx deal -sources

NEW YORK - Amgen Inc, the world's largest biotechnology company, has lined up Bank of America Corp, JPMorgan Chase & Co and Barclays Plc to finance a potential deal for Onyx Pharmaceuticals Inc, according to three people familiar with the matter.

24 Jul 2013

DEALTALK-Biotech takeover interest more fad than fashion

July 19 - Investors betting on a wave of big biotechnology deals following Amgen Inc's $10 billion bid for Onyx Pharmaceuticals Inc may well be disappointed.

19 Jul 2013

Exclusive: Pfizer not moving forward with Onyx bid: sources

NEW YORK - Pfizer Inc decided not to pursue a bid for Onyx Pharmaceuticals Inc this week, according to two people familiar with the matter, leaving Amgen Inc in the front position to buy the cancer drugmaker.

18 Jul 2013

Initial takeover bids for Onyx seen as soon as this week: sources

NEW YORK - Onyx Pharmaceuticals Inc is expected to receive initial takeover bids as soon as this week after attracting interest from a few drugmakers, including Amgen Inc , according to several people familiar with the matter.

16 Jul 2013

UPDATE 2-Initial takeover bids for Onyx seen as soon as this week-sources

NEW YORK, July 16 - Onyx Pharmaceuticals Inc is expected to receive initial takeover bids as soon as this week after attracting interest from a few drugmakers, including Amgen Inc, according to several people familiar with the matter.

16 Jul 2013

Initial takeover bids for Onyx seen as soon as this week -sources

NEW YORK, July 16 - Onyx Pharmaceuticals Inc is expected to receive first-round offers as soon as this week after attracting takeover interest from a few drugmakers including Amgen Inc, according to several people familiar with the matter.

16 Jul 2013

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$58.00
Provider: Stock Traders Daily
$495.00
Provider: S&P Capital IQ – STARS Reports
$138.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks